Compare COVID-19 Oral Antivirals
You'll be asked about the new COVID-19 oral antivirals nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.
Eligibility. Educate that these meds are for outpatients with a positive COVID-19 test who are at high risk of developing severe illness (diabetes, etc)...regardless of vaccination status.
Nirmatrelvir/ritonavir is for age 12 and up...molnupiravir is for 18 and up. Either is started within 5 days of symptoms...and used bid for 5 days. Patients don't currently have to pay for them.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote